Clinical implications of recent findings in schistosome proteomics

Expert Review of Proteomics

Volumn 13, Issue 1, 2016, Pages 19-33

  Driguez, Patrick ^a   McManus, Donald P ^a   Gobert, Geoffrey N ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Antigen discovery; Diagnosis; Drug target; Immunoproteomics; Proteomics; Schistosomiasis; Vaccine

Indexed keywords

BIOLOGICAL MARKER; HELMINTH PROTEIN; PROTEOME;

BIOLOGY; HIGH THROUGHPUT SEQUENCING; HOST PARASITE INTERACTION; LIFE CYCLE; MAMMAL; METABOLOMICS; NONHUMAN; PARASITE; PROTEOMICS; REVIEW; SCHISTOSOMA; SCHISTOSOMIASIS; TRANSCRIPTOMICS; ANIMAL; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; PARASITOLOGY; PHYSIOLOGY;

ANIMALS; HELMINTH PROTEINS; HOST-PATHOGEN INTERACTIONS; HUMANS; PROTEOME; PROTEOMICS; SCHISTOSOMA; SCHISTOSOMIASIS;

EID: 84948151693     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.2016.1116390     Document Type: Review

References (109)

1. WHO. Schistosomiasis: number of people treated worldwide in 2013. Wkly Epidemiol Rec. 2015;90:25-32.
2. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2013;380:2197-2223.
3. Pearce EJ, MacDonald AS. The immunobiology of schistosomiasis. Nat Rev Immunol. 2002;2:499-511.
4. Wilson MS, Mentink-Kane MM, Pesce JT, et al. Immunopathology of schistosomiasis. Immunol Cell Biol. 2007;85:148-154.
5. Gryseels B, Polman K, Clerinx J, et al. Human schistosomiasis. Lancet. 2006;368:1106-1118.
6. Rinaldi G, Young ND, Honeycutt JD, et al. New research tools for urogenital schistosomiasis. J Infect Dis. 2015;211:861-869.
7. Gray DJ, Ross AG, Li YS, et al. Diagnosis and management of schistosomiasis. BMJ. 2011;342:d2651.
8. Doenhoff MJ, Cioli D, Utzinger J. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis. 2008;21:659-667.
9. Gobert GN, Jones MK. Discovering new schistosome drug targets: the role of transcriptomics. Curr Drug Targets. 2008;9:922-930.
10. Gray DJ, McManus DP, Li Y, et al. Schistosomiasis elimination: lessons from the past guide the future. Lancet Infect Dis. 2010;10:733-736.
11. You H, McManus DP, Gobert GN. Current and prospective chemotherapy options for schistosomiasis. Expert Opin Orphan Drugs. 2015;3:195-205.
12. Fonseca CT, Oliveira SC, Alves CC. Eliminating schistosomes through vaccination: what are the best immune weapons? Front Immunol. 2015;6:95.
13. Berriman M, Haas BJ, LoVerde PT, et al. The genome of the blood fluke Schistosoma mansoni. Nature. 2009;460:352-358. The complete Schistosoma mansoni genome.
14. Liu F, Zhou Y, Wang ZQ, et al. The Schistosoma japonicum genome reveals features of host-parasite interplay. Nature. 2009;460:345-351. The complete Schistosoma japonicum genome.
15. Young ND, Jex AR, Li B, et al. Wholegenome sequence of Schistosoma haematobium. Nat Genet. 2012;44:221-225. The complete Schistosoma haematobium genome.
16. Liu F, Lu J, Hu W, et al. New perspectives on host-parasite interplay by comparative transcriptomic and proteomic analyses of Schistosoma japonicum. PLoS Pathog. 2006;2:e29., Important study combining extensive transcriptomics and shotgun proteomics of S. japonicum.
17. Sotillo J, Pearson M, Becker L, et al. A quantitative proteomic analysis of the tegumental proteins from Schistosoma mansoni schistosomula reveals novel potential therapeutic targets. Int J Parasitol. 2015;45:505-516. Proteomic identification of surface antigens on schistosomula using biotinylation.
18. De la Torre Escudero E, Manzano-Roman R, Valero L, et al. Comparative proteomic analysis of Fasciola hepatica juveniles and Schistosoma bovis schistosomula. J Proteomics. 2011;74:1534-1544.
19. Higon M, Cowan G, Nausch N, et al. Screening trematodes for novel intervention targets: a proteomic and immunological comparison of Schistosoma haematobium, Schistosoma bovis and Echinostoma caproni. Parasitology. 2011;138:1607-1619.
20. Knudsen GM, Medzihradszky KF, Lim K-C, et al. Proteomic analysis of Schistosoma mansoni cercarial secretions. Mol Cell Proteomics. 2005;4:1862-1875.
21. Hansell E, Braschi S, Medzihradszky KF, et al. Proteomic analysis of skin invasion by blood fluke larvae. PLoS Negl Trop Dis. 2008;2:e262.
22. Kariuki TM, Farah IO, Wilson RA, et al. Antibodies elicited by the secretions from schistosome cercariae and eggs are predominantly against glycan epitopes. Parasite Immunol. 2008;30:554-562.
23. Guillou F, Roger E, Mone Y, et al. Excretory-secretory proteome of larval Schistosoma mansoni and Echinostoma caproni, two parasites of Biomphalaria glabrata. Mol Biochem Parasitol. 2007;155:45-56.
24. Ridi RE, Tallima H. Schistosoma mansoni ex vivo lung-stage larvae excretory-secretory antigens as vaccine candidates against schistosomiasis. Vaccine. 2009;27:666-673.
25. Hall SL, Braschi S, Truscott M, et al. Insights into blood feeding by schistosomes from a proteomic analysis of worm vomitus. Mol Biochem Parasitol. 2011;179:18-29.
26. Wang J, Zhao F, Yu C-X, et al. Identification of proteins inducing shortlived antibody responses from excreted/secretory products of Schistosoma japonicum adult worms by immunoproteomic analysis. J Proteomics. 2013;87:53-67.
27. Liu F, Cui SJ, Hu W, et al. Excretory/secretory proteome of the adult developmental stage of human blood fluke, Schistosoma japonicum. Mol Cell Proteomics. 2009;8:1236-1251.
28. Cass CL, Johnson JR, Califf LL, et al. Proteomic analysis of Schistosoma mansoni egg secretions. Mol Biochem Parasitol. 2007;155:84-93.
29. Dewalick S, Bexkens ML, van Balkom BWM, et al. The proteome of the insoluble Schistosoma mansoni eggshell skeleton. Int J Parasitol. 2011;41:523-532.
30. Mathieson W, Wilson RA A comparative proteomic study of the undeveloped and developed Schistosoma mansoni egg and its contents: the miracidium, hatch fluid and secretions. Int J Parasitol. 2010;40:617-628.
31. Mutapi F, Burchmore R, Mduluza T, et al. Praziquantel treatment of individuals exposed to Schistosoma haematobium enhances serological recognition of defined parasite antigens. J Infect Dis. 2005;192:1108-1118., One of the earliest human immunoprotomics studies on the schistosomes.
32. Mutapi F, Bourke C, Harcus Y, et al. Differential recognition patterns of Schistosoma haematobium adult worm antigens by the human antibodies IgA, IgE, IgG1 and IgG4. Parasite Immunol. 2011;33:181-192.
33. Zhong ZR, Zhou HB, Li XY, et al. Serological proteome-oriented screening and application of antigens for the diagnosis of schistosomiasis japonica. Acta Trop. 2010;116:1-8.
34. Boamah D, Kikuchi M, Huy NT, et al. Immunoproteomics identification of major IgE and IgG4 reactive Schistosoma japonicum adult worm antigens using chronically infected human plasma. Trop Med Health. 2012;40:89-102.
35. Liu F, Hu W, Cui SJ, et al. Insight into the host-parasite interplay by proteomic study of host proteins copurified with the human parasite, Schistosoma japonicum. Proteomics. 2007;7:450-462.
36. Neves L, Sanson A, Wilson R, et al. Whats in SWAP? Abundance of the principal constituents in a soluble extract of Schistosoma mansoni revealed by shotgun proteomics. Parasit Vectors. 2015;8:337.
37. Gaze S, Driguez P, Pearson MS, et al. An immunomics approach to schistosome antigen discovery: antibody signatures of naturally resistant and chronically infected individuals from endemic areas. PLoS Pathog. 2014;10:e1004033., Schistosome protein microarray used with humans naturally resistant to and with chronic S. mansoni infection. Putative vaccine candidates identified.
38. Pearson M, Becker L, Driguez P, et al. Of monkeys and men: immunomic profiling of sera from humans and non-human primates resistant to schistosomiasis reveals novel potential vaccine candidates. Front Immunol. 2015;6:216.
39. Driguez P, McWilliam HE, Gaze S, et al. Specific humoral response of hosts with variable schistosomiasis susceptibility. Immunol Cell Biol. 2015. DOI:10.1038/icb.2015.61. [Epub ahead of print].
40. Driguez P, Li Y, Gaze S, et al. Antibody signatures reflect different disease pathologies in patients with schistosomiasis due to Schistosoma japonicum. J Infect Dis. 2015. pii:jiv356. [Epub ahead of print].
41. McWilliam H, Driguez P, Piedrafita D, et al. Discovery of novel Schistosoma japonicum antigens using a targeted protein microarray approach. Parasit Vectors. 2014;7:290.
42. Chen J-H, Zhang T, Ju C, et al. An integrated immunoproteomics and bioinformatics approach for the analysis of Schistosoma japonicum tegument proteins. J Proteomics. 2014;98:289-299.
43. Xu X, Zhang Y, Lin D, et al. Serodiagnosis of Schistosoma japonicum infection: genome-wide identification of a protein marker, and assessment of its diagnostic validity in a field study in China. Lancet Infect Dis. 2014;14:489-497., Protein microplate array used to identify an important diagnostic antigen after screening with S. japonicum infected human sera. Diagnostic antigen found to have excellent potential after extensive testing in field.
44. Harvie M, Jordan TW, La Flamme AC. Differential liver protein expression during schistosomiasis. Infect Immun. 2007;75:736-744.
45. Manivannan B, Jordan TW, Secor WE, et al. Proteomic changes at 8 weeks after infection are associated with chronic liver pathology in experimental schistosomiasis. J Proteomics. 2012;75:1838-1848.
46. De La Torre-Escudero E, Perez-Sanchez R, Manzano-Roman R, et al. Schistosome infections induce significant changes in the host biliary proteome. J Proteomics. 2015;114:71-82.
47. Ferreira MS, De Oliveira DN, De Oliveira RN, et al. Mass spectrometry imaging: a new vision in differentiating Schistosoma mansoni strains. J Mass Spectrom. 2014;49:86-92., First MALDI-TOF MS imaging study on schistosomes.
48. Ferreira MS, de Oliveira RN, de Oliveira DN, et al. Revealing praziquantel molecular targets using mass spectrometry imaging: an expeditious approach applied to Schistosoma mansoni. Int J Parasitol. 2015;45:385-391.
49. Mulvenna J, Moertel L, Jones MK, et al. Exposed proteins of the Schistosoma japonicum tegument. Int J Parasitol. 2010;40:543-554.
50. Braschi S, Wilson RA. Proteins exposed at the adult schistosome surface revealed by biotinylation. Mol Cell Proteomics. 2006;5:347-356., Early biotinylation study of a schistosome species.
51. Braschi S, Borges WC, Wilson RA. Proteomic analysis of the schistosome tegument and its surface membranes. Mem Inst Oswaldo Cruz. 2006;101(Suppl 1):205-212.
52. Zhang M, Hong Y, Han Y, et al. Proteomic analysis of tegument-exposed proteins of female and male Schistosoma japonicum worms. J Proteome Res. 2013;12:5260-5270.
53. Braschi S, Curwen RS, Ashton PD, et al. The tegument surface membranes of the human blood parasite Schistosoma mansoni: a proteomic analysis after differential extraction. Proteomics. 2006;6:1471-1482.
54. Curwen RS, Ashton PD, Johnston DA, et al. The Schistosoma mansoni soluble proteome: a comparison across four lifecycle stages. Mol Biochem Parasitol. 2004;138:57-66.
55. Dalton JP, Skelly P, Halton DW. Role of the tegument and gut in nutrient uptake by parasitic platyhelminths. Can J Zool. 2004;82:211-232.
56. Skelly PJ, Wilson RA. Making sense of the schistosome surface. Adv Parasitol. 2006;63:185-284., Seminal review of the schistosome tegument surface.
57. Skelly PJ, Kim JW, Cunningham J, et al. Cloning, characterization, and functional expression of cDNAs encoding glucose transporter proteins from the human parasite Schistosoma mansoni. J Biol Chem. 1994;269:4247-4253.
58. Gobert GN, Stenzel DJ, McManus DP, et al. The ultrastructural architecture of the adult Schistosoma japonicum tegument. Int J Parasitol. 2003;33:1561-1575.
59. Jones MK, Gobert GN, Zhang L, et al. The cytoskeleton and motor proteins of human schistosomes and their roles in surface maintenance and host-parasite interactions. Bioessays. 2004;26:752-765.
60. You H, Gobert GN, Duke MG, et al. The insulin receptor is a transmission blocking veterinary vaccine target for zoonotic Schistosoma japonicum. Int J Parasitol. 2012;42:801-807.
61. Dissous C, Khayath N, Vicogne J, et al. Growth factor receptors in helminth parasites: signalling and host-parasite relationships. FEBS Lett. 2006;580:2968-2975.
62. Wilson RA. Proteomics at the schistosome-mammalian host interface: any prospects for diagnostics or vaccines? Parasitology. 2012;139:1178-1194.
63. Toh SQ, Glanfield A, Gobert GN, et al. Heme and blood-feeding parasites: friends or foes? Parasit Vectors. 2010;3:108.
64. Gobert GN, McManus DP, Nawaratna S, et al. Tissue-specific profiling of females of Schistosoma japonicum by integrated laser microdissection microscopy and microarray analysis. PLoS Negl Trop Dis. 2009;3:e469.
65. Nawaratna SS, Gobert GN, Willis C, et al. Transcriptional profiling of the oesophageal gland region of male worms of Schistosoma mansoni. Mol Biochem Parasitol. 2014;196:82-89.
66. Nawaratna SS, McManus DP, Moertel L, et al. Gene Atlasing of digestive and reproductive tissues in Schistosoma mansoni. PLoS Negl Trop Dis. 2011;5:e1043.
67. Delcroix M, Medzihradsky K, Caffrey CR, et al. Proteomic analysis of adult S.mansoni gut contents. Mol Biochem Parasitol. 2007;154:95-97.
68. Wilson RA. The saga of schistosome migration and attrition. Parasitology. 2009;136:1581-1592.
69. Chai M, McManus DP, McInnes R, et al. Transcriptome profiling of lung schistosomula, in vitro cultured schistosomula and adult Schistosoma japonicum. Cell Mol Life Sci. 2006;63:919-929.
70. Protasio AV, Dunne DW, Berriman M. Comparative study of transcriptome profiles of mechanical- and skin-transformed Schistosoma mansoni schistosomula. PLoS Negl Trop Dis. 2013;7:e2091.
71. Loukas A, Gaze S, Mulvenna JP, et al. Vaccinomics for the major blood feeding helminths of humans. OMICS. 2011;15:567-577.
72. Fonseca CT, Braz Figueiredo Carvalho G, Carvalho Alves C, et al. Schistosoma tegument proteins in vaccine and diagnosis development: an update. J Parasitol Res. 2012;2012:541268.
73. Everts B, Perona-Wright G, Smits HH, et al. Omega-1, a glycoprotein secreted by Schistosoma mansoni eggs, drives Th2 responses. J Exp Med. 2009;206:1673-1680.
74. Wuhrer M, Balog CI, Catalina MI, et al. IPSE/alpha-1, a major secretory glycoprotein antigen from schistosome eggs, expresses the Lewis X motif on coredifucosylated N-glycans. FEBS J. 2006;273:2276-2292.
75. Abdulla MH, Lim KC, McKerrow JH, et al. Proteomic identification of IPSE/alpha-1 as a major hepatotoxin secreted by Schistosoma mansoni eggs. PLoS Negl Trop Dis. 2011;5:e1368.
76. Lamberton PHL, Kabatereine NB, Oguttu DW, et al. Sensitivity and specificity of multiple kato-katz thick smears and a circulating cathodic antigen test for Schistosoma mansoni diagnosis pre- and post-repeated-praziquantel treatment. PLoS Negl Trop Dis. 2014;8:e3139.
77. Mickum ML, Prasanphanich NS, Heimburg-Molinaro J, et al. Deciphering the glycogenome of schistosomes. Front Genet. 2014;5:262.
78. Bickle QD. Radiation-attenuated schistosome vaccination -A brief historical perspective. Parasitology. 2009;136:1621-1632.
79. Castro-Borges W, Dowle A, Curwen RS, et al. Enzymatic shaving of the tegument surface of live schistosomes for proteomic analysis: a rational approach to select vaccine candidates. PLoS Negl Trop Dis. 2011;5:e993.
80. Castro-Borges W, Simpson DM, Dowle A, et al. Abundance of tegument surface proteins in the human blood fluke Schistosoma mansoni determined by QconCAT proteomics. J Proteomics. 2011;74:1519-1533.
81. Skelly PJ. Intravascular schistosomes and complement. Trends Parasitol. 2004;20:370-374.
82. Wu C, Hou N, Piao X, et al. Non-immune immunoglobulins shield Schistosoma japonicum from host immunorecognition. Scientific Reports. 2015;5:13434.
83. Doolan DL, Aguiar JC, Weiss WR, et al. Utilization of genomic sequence information to develop malaria vaccines. J Exp Biol. 2003;206:3789-3802.
84. Davies DH, Liang X, Hernandez JE, et al. Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery. Proc Natl Acad Sci USA. 2005;102:547-552.
85. Driguez P, Doolan DL, Loukas A, et al. Schistosomiasis vaccine discovery using immunomics. Parasit Vectors. 2010;3:4., First schistosome protein microarray for immunoproteomics.
86. Doolan DL. Plasmodium immunomics. Int J Parasitol. 2011;41:3-20.
87. Driguez P, Doolan D, Molina D, et al. Protein microarrays for parasite antigen discovery. In: Peacock C, editor. Parasite genomics protocols. New York (NY): Springer; 2015. p. 221-233.
88. Silva-Moraes V, Ferreira JM, Coelho PM, et al. Biomarkers for schistosomiasis: towards an integrative view of the search for an effective diagnosis. Acta Trop. 2014;132:75-79.
89. Ludolf F, Patrocinio PR, Correa-Oliveira R, et al. Serological screening of the Schistosoma mansoni adult worm proteome. PLoS Negl Trop Dis. 2014;8:e2745.
90. Clinical. Trials.gov, National Institute of Health. Study to evaluate the safety of the vaccine prepared sm14 against schistosomiasis. Oswaldo Cruz Foundation; 2013. [cited 2015 Oct. 9]. Available from: http://clinicaltrials.gov/ct2/show/study/NCT01154049.
91. Riveau G, Deplanque D, Remoue F, et al. Safety and immunogenicity of rSh28GST antigen in humans: Phase 1 randomized clinical study of a vaccine candidate against urinary schistosomiasis. PLoS Negl Trop Dis. 2012;6:e1704.
92. Curti E, Kwityn C, Zhan B, et al. Expression at a 20L scale and purification of the extracellular domain of the Schistosoma mansoni TSP-2 recombinant protein: a vaccine candidate for human intestinal schistosomiasis. Hum Vaccin Immunother. 2013;9:2342-2350.
93. Cheng W, Curti E, Rezende WC, et al. Biophysical and formulation studies of the Schistosoma mansoni TSP-2 extracellular domain recombinant protein, a lead vaccine candidate antigen for intestinal schistosomiasis. Hum Vaccin Immunother. 2013;9:2351-2361.
94. Chuah C, Jones MK, Burke ML, et al. Spatial and temporal transcriptomics of Schistosoma japonicum-induced hepatic granuloma formation reveals novel roles for neutrophils. J Leukoc Biol. 2013;94:353-365.
95. Perry CR, Burke ML, Stenzel DJ, et al. Differential expression of chemokine and matrix re-modelling genes is associated with contrasting schistosome-induced hepatopathology in murine models. PLoS Negl Trop Dis. 2011;5:e1178.
96. Fu CL, Odegaard JI, Herbert DR, et al. A novel mouse model of Schistosoma haematobium egg-induced immunopathology. PLoS Pathog. 2012;8:e1002605.
97. Brophy PM, MacKintosh N, Morphew RM. Anthelmintic metabolism in parasitic helminths: proteomic insights. Parasitology. 2012;139:1205-1217.
98. Barrett J. Helminth detoxification mechanisms. J Helminthol. 1997;71:85-89.
99. Chemale G, Perally S, LaCourse EJ, et al. Comparative proteomic analysis of triclabendazole response in the liver fluke Fasciola hepatica. J Proteome Res. 2010;9:4940-4951.
100. Perez-Sanchez R, Ramajo-Hernandez A, Ramajo-Martin V, et al. Proteomic analysis of the tegument and excretory-secretory products of adult Schistosoma bovis worms. Proteomics. 2006;6(Suppl 1):S226-S236.
101. Gobert GN, Stenzel DJ, Jones MK, et al. Immunolocalization of the fatty acidbinding protein Sj-FABPc within adult Schistosoma japonicum. Parasitology. 1997;115(Pt 1):33-39.
102. De Souza AL, Andreani T, De Oliveira RN, et al. In vitro evaluation of permeation, toxicity and effect of praziquantelloaded solid lipid nanoparticles against Schistosoma mansoni as a strategy to improve efficacy of the schistosomiasis treatment. Int J Pharm. 2014;463:31-37.
103. Pica-Mattoccia L, Cioli D. Sex- and stage-related sensitivity of Schistosoma mansoni to in vivo and in vitro praziquantel treatment. Int J Parasitol. 2004;34:527-533.
104. You H, McManus DP, Hu W, et al. Transcriptional responses of in vivo praziquantel exposure in schistosomes identifies a functional role for calcium signalling pathway member CamKII. PLoS Pathog. 2013;9:e1003254.
105. Ricciardi A, Ndao M. Still hope for schistosomiasis vaccine. Hum Vaccin Immunother. Forthcoming 2015. DOI:10.1080/21645515.21642015.21059981.
106. Diniz PP, Nakajima E, Miyasato PA, et al. Two SmDLC antigens as potential vaccines against schistosomiasis. Acta Trop. 2014;140C:193-201.
107. Brindley PJ, Hotez PJ. Break out: urogenital schistosomiasis and Schistosoma haematobium infection in the postgenomic era. PLoS Negl Trop Dis. 2013;7:e1961.
108. Homann M, Goringer HU. Uptake and intracellular transport of RNA aptamers in African trypanosomes suggest therapeutic "piggy-back" approach. Bioorg Med Chem. 2001;9:2571-2580.
109. Andrews KT, Fisher G, Skinner-Adams TS. Drug repurposing and human parasitic protozoan diseases. Int J Parasitol Drugs Drug Resist. 2014;4:95-111.